Literature DB >> 1654781

Reductive metabolism of nitroprusside in rat hepatocytes and human erythrocytes.

D N Rao1, S Elguindi, P J O'Brien.   

Abstract

The metabolism of nitroprusside by hepatocytes or subcellular fractions involves a one-electron reduction of nitroprusside to the corresponding metal-nitroxyl radical. Thiol compounds also reduced nitroprusside to the metal-nitroxyl radical apparently via a thiol adduct. The nitroprusside reduction by microsomes was shown to be due to cytochrome P450 reductase as an antibody to cytochrome P450 reductase inhibits the microsomal reduction of nitroprusside, and the inhibitors of cytochrome P450 such as carbon monoxide or metyrapone had no effect. The reduction of nitroprusside by mitochondria in the presence of NADH or NADPH also produced the metal-nitroxyl radical. In hepatocytes, both mitochondria and the cytochrome P450 reductase are involved in the reduction of nitroprusside. The reductive metabolism of nitroprusside was found to produce toxic by-products, namely, free cyanide anion and hydrogen peroxide. We have also detected thiyl radicals formed in the thiol compound reduction of NP. We propose that cyanide and hydrogen peroxide are important toxic species formed in the metabolism of nitroprusside. The rate of reductive metabolism of nitroprusside by rat hepatocytes was much higher than with human erythrocytes. Therefore the major site of nitroprusside metabolism in vivo may be liver and not blood as originally proposed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654781     DOI: 10.1016/0003-9861(91)90005-4

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production.

Authors:  R Ferrero; F Rodríguez-Pascual; M T Miras-Portugal; M Torres
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Amphotericin B severely affects expression and activity of the endothelial constitutive nitric oxide synthase involving altered mRNA stability.

Authors:  C V Suschek; E Bonmann; H Kleinert; M Wenzel; C Mahotka; H Kolb; U Förstermann; C D Gerharz; V Kolb-Bachofen
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

3.  Nitric oxide and sodium nitroprusside-induced relaxation of the human umbilical artery.

Authors:  F Lovren; C Triggle
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

4.  Inhibition of cytochromes P4501A by nitric oxide.

Authors:  J Stadler; J Trockfeld; W A Schmalix; T Brill; J R Siewert; H Greim; J Doehmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro.

Authors:  Sara M Thomazzi; Juliana Moreira; Sisi Marcondes; Gilberto De Nucci; Edson Antunes
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

6.  Sodium nitroprusside promotes IRP2 degradation via an increase in intracellular iron and in the absence of S nitrosylation at C178.

Authors:  Jian Wang; Carine Fillebeen; Guohua Chen; Bill Andriopoulos; Kostas Pantopoulos
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  The NO donor sodium nitroprusside: evaluation of skeletal muscle vascular and metabolic dysfunction.

Authors:  Daniel M Hirai; Steven W Copp; Scott K Ferguson; Clark T Holdsworth; Timothy I Musch; David C Poole
Journal:  Microvasc Res       Date:  2012-11-19       Impact factor: 3.514

8.  Glyceraldehyde-3-phosphate dehydrogenase is required for the transport of nitric oxide in platelets.

Authors:  B McDonald; B Reep; E G Lapetina; L Molina y Vedia
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

Review 9.  Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease.

Authors:  Mingyue He; Deping Wang; Yumei Xu; Fangying Jiang; Jian Zheng; Yanlin Feng; Jimin Cao; Xin Zhou
Journal:  Pharmaceutics       Date:  2022-06-25       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.